Platelet substitutes and novel methods of platelet preservation

Platelets

Volumn , Issue , 2007, Pages 1297-1309

  Lee, David H ^a   Blajchman, Morris A ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884757010     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369367-9/50832-6     Document Type: Chapter

References (132)

1. Klein E., Toch R., Farber S., et al. Hemostasis in thrombocytopenic bleeding following infusion of stored, frozen platelets. Blood 1956, 11:693-999.
2. Tullis J.L., Surgenor D.M., Baudanza P. Preserved platelets: Their preparation, storage and clinical use. Blood 1959, 14:456-475.
3. Schiffer C.A., Aisner J., Wiernik P.H. Frozen autologous platelet transfusion for patients with leukemia. N Engl J Med 1978, 299:7-12.
4. Khuri S.F., Healey N., MacGregor H., et al. Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999, 117:172-184.
5. Yokomuro M., Ebine K., Shiroma K., et al. Safety and efficacy of autologous platelet transfusion in cardiac surgery: Comparison of cryopreservation, blood collection on the day before surgery, and blood collection during surgery. Cryobiology 1999, 38:236-242.
6. Valeri C.R., Feingold H., Marchionni L.D. A simple method for freezing human platelets using 6 percent dimethylsulfoxide and storage at .80 degrees C. Blood 1974, 43:131-136.
7. Daly P.A., Schiffer C.A., Aisner J., et al. Successful transfusion of platelets cryopreserved for more than 3 years. Blood 1979, 54:1023-1027.
8. Valeri C.R. The current state of platelet and granulocyte cryopreservation. Crit Rev Clin Lab Sci 1981, 14:21-74.
9. Melaragno A.J., Carciero R., Feingold H., et al. Cryopreservation of human platelets using 6% dimethyl sulfoxide and storage at .80 degrees C. Effects of 2 years of frozen storage at .80 degrees C and transportation in dry ice. Vox Sang 1985, 49:245-258.
10. Valeri C.R., Srey R., Lane J.P., et al. Effect of WBC reduction and storage temperature on PLTs frozen with 6 percent DMSO for as long as 3 years. Transfusion 2003, 43:1162-1167.
11. Melaragno A.J., Abdu W.A., Katchis R.J., et al. Cryopreservation of platelets isolated with the IBM 2997 blood cell separator: A rapid and simplified approach. Vox Sang 1982, 43:321-326.
12. Angelini A., Dragani A., Berardi A., et al. Evaluation of four different methods for platelet freezing. In vitro and in vivo studies. Vox Sang 1992, 62:146-151.
13. Vecchione J.J., Melaragno A.J., Hollander A., et al. Circulation and function of human platelets isolated from units of CPDA-1, CPDA-2, and CPDA-3 anticoagulated blood and frozen with DMSO. Transfusion 1982, 22:206-209.
14. Owens M., Cimino C., Donnelly J. Cryopreserved platelets have decreased adhesive capacity. Transfusion 1991, 31:160-163.
15. Dullemond-Westland A.C., van Prooijen H.C., Riemens M.I., et al. Cryopreservation disturbs stimulusresponse coupling in a platelet subpopulation. Br J Haematol 1987, 67:325-333.
16. Shepherd K.M., Sage R.E., Barber S., et al. Platelet cryopreservation: 1. In vitro aggregation studies. Cryobiology 1984, 21:39-43.
17. Spector J.I., Skrabut E.M., Valeri C.R. Oxygen consumption, platelet aggregation and release reactions in platelets freeze-preserved with dimethylsulfoxide. Transfusion 1977, 17:99-109.
18. Spector J.I., Flor W.J., Valeri C.R. Ultrastructural alterations and phagocytic function of cryopreserved platelets. Transfusion 1979, 19:307-312.
19. Owens M., Werner E., Holme S., et al. Membrane glycoproteins in cryopreserved platelets. Vox Sang 1994, 67:28-31.
20. Barnard M.R., MacGregor H., Ragno G., et al. Fresh, liquid-preserved, and cryopreserved platelets: Adhesive surface receptors and membrane procoagulant activity. Transfusion 1999, 39:880-888.
21. Currie L.M., Livesey S.A., Harper J.R., et al. Cryopreservation of single-donor platelets with a reduced dimethyl sulfoxide concentration by the addition of secondmessenger effectors: Enhanced retention of in vitro functional activity. Transfusion 1998, 38:160-167.
22. Lozano M., Escolar G., Mazzara R., et al. Effects of the addition of second-messenger effectors to platelet concentrates separated from whole-blood donations and stored at 4 degrees C or .80 degrees C. Transfusion 2000, 40:527-534.
23. Lozano M.L., Rivera J., Corral J., et al. Platelet cryopreservation using a reduced dimethyl sulfoxide concentration and second-messenger effectors as cryopreserving solution. Cryobiology 1999, 39:1-12.
24. Currie L.M., Lichtiger B., Livesey S.A., et al. Enhanced circulatory parameters of human platelets cryopreserved with second-messenger effectors: An in vivo study of 16 volunteer platelet donors. Br J Haematol 1999, 105:826-831.
25. Vadhan-Raj S., Currie L.M., Bueso-Ramos C., et al. Enhanced retention of in vitro functional activity of platelets from recombinant human thrombopoietin-treated patients following long-term cryopreservation with a platelet-preserving solution (ThromboSol) and 2% DMSO. Br J Haematol 1999, 104:403-411.
26. Vadhan-Raj S., Kavanagh J.J., Freedman R.S., et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: A randomised cross-over study. Lancet 2002, 359:2145-2152.
27. Nie Y., de Pablo J.J., Palecek S.P. Platelet cryopreservation using a trehalose and phosphate formulation. Biotechnol Bioeng 2005, 92:79-90.
28. Murphy S., Gardner F.H. Effect of storage temperature on maintenance of platelet viability -Deleterious effect of refrigerated storage. N Engl J Med 1969, 280:1094-1098.
29. Slichter S.J., Harker L.A. Preparation and storage of platelet concentrates: II. Storage variables influencing platelet viability and function. Br J Haematol 1976, 34:403-419.
30. Filip D.J., Aster R.H. Relative hemostatic effectiveness of human platelets stored at 4 degrees and 22 degrees C. J Lab Clin Med 1978, 91:618-624.
31. Kaufman R.M. Uncommon cold: Could 4 degrees C storage improve platelet function?. Transfusion 2005, 45:1407-1412.
32. Hoffmeister K.M., Felbinger T.W., Falet H., et al. The clearance mechanism of chilled blood platelets. Cell 2003, 112:87-97.
33. Josefsson E.C., Gebhard H.H., Stossel T.P., et al. The macrophage alphaMbeta2 integrin alphaM lectin domain mediates the phagocytosis of chilled platelets. J Biol Chem 2005, 280:18025-18032.
34. Hoffmeister K.M., Josefsson E.C., Isaac N.A., et al. Glycosylation restores survival of chilled blood platelets. Science 2003, 301:1531-1534.
35. Connor J., Currie L.M., Allan H., et al. Recovery of in vitro functional activity of platelet concentrates stored at 4 degrees C and treated with second-messenger effectors. Transfusion 1996, 36:691-698.
36. Rivera J., Lozano M.L., Corral J., et al. Quality assessment of platelet concentrates supplemented with second-messenger effectors. Transfusion 1999, 39:135-143.
37. Winokur R., Hartwig J.H. Mechanism of shape change in chilled human platelets. Blood 1995, 85:1796-1804.
38. Valeri C.R., Ragno G., Marks P.W., et al. Effect of thrombopoietin alone and a combination of cytochalasin B and ethylene glycol bis (beta-aminoethyl ether) N,N.-tetraacetic acid-AM on the survival and function of autologous baboon platelets stored at 4 degrees C for as long as 5 days. Transfusion 2004, 44:865-870.
39. Tablin F., Oliver A.E., Walker N.J., et al. Membrane phase transition of intact human platelets: Correlation with cold-induced activation. J Cell Physiol 1996, 168:305-313.
40. Allain J.P., Bianco C., Blajchman M.A., et al. Protecting the blood supply from emerging pathogens: The role of pathogen inactivation. Transfus Med Rev 2005, 19:110-126.
41. Cimino G.D., Gamper H.B., Isaacs S.T., et al. Psoralens as photoactive probes of nucleic acid structure and function: Organic chemistry, photochemistry, and biochemistry. Annu Rev Biochem 1985, 54:1151-1193.
42. Lin L., Cook D.N., Wiesehahn G.P., et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997, 37:423-435.
43. Grass J.A., Hei D.J., Metchette K., et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998, 91:2180-2188.
44. Van Voorhis W.C., Barrett L.K., Eastman R.T., et al. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 2003, 47:475-479.
45. Picker S.M., Speer R., Gathof B.S. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004, 44:320-329.
46. Hei D.J., Grass J., Lin L., et al. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999, 39:239-248.
47. Grass J.A., Wafa T., Reames A., et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999, 93:3140-3147.
48. van Rhenen D., Gulliksson H., Cazenave J.P., et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The euroSPRITE trial. Blood 2003, 101:2426-2433.
49. McCullough J., Vesole D.H., Benjamin R.J., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT trial. Blood 2004, 104:1534-1541.
50. Janetzko K., Cazenave J.P., Kluter H., et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005, 45:1443-1452.
51. Snyder E., Raife T., Lin L., et al. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004, 44:1732-1740.
52. Hoffmann M.E., Meneghini R. DNA strand breaks in mammalian cells exposed to light in the presence of riboflavin and tryptophan. Photochem Photobiol 1979, 29:299-303.
53. Kumar V., Lockerbie O., Keil S.D., et al. Riboflavin and UV-light based pathogen reduction: Extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004, 80:15-21.
54. Tsugita A., Okada Y., Uehara K. Photosensitized inactivation of ribonucleic acids in the presence of riboflavin. Biochim Biophys Acta 1965, 103:360-363.
55. Goodrich R.P. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 2000, 78(Suppl. 2):211-215.
56. Ruane P.H., Edrich R., Gampp D., et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004, 44:877-885.
57. Perez-Pujol S., Tonda R., Lozano M., et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005, 45:911-919.
58. Li J., de Korte D., Woolum M.D., et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: Comparisons with pathogen-reduction technologytreated apheresis platelet products. Vox Sang 2004, 87:82-90.
59. Li J., Lockerbie O., de Korte D., et al. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 2005, 45:920-926.
60. AuBuchon J.P., Herschel L., Roger J., et al. Effi-cacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005, 45:1335-1341.
61. Owens M.R. The role of platelet microparticles in hemostasis. Transfus Med Rev 1994, 8:37-44.
62. Solberg C., Holme S., Little C. Morphological changes associated with pH changes during storage of platelet concentrates in first-generation 3-day container. Vox Sang 1986, 50:71-77.
63. George J.N., Pickett E.B., Heinz R. Platelet membrane glycoprotein changes during the preparation and storage of platelet concentrates. Transfusion 1988, 28:123-126.
64. Bode A.P., Orton S.M., Frye M.J., et al. Vesiculation of platelets during in vitro aging. Blood 1991, 77:887-895.
65. George J.N., Pickett E.B., Heinz R. Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate. Blood 1986, 68:307-309.
66. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967, 13:269-288.
67. Solberg C., Osterud B., Little C. Platelet storage lesion: Formation of platelet fragments with platelet factor 3 activity. Thromb Res 1987, 48:559-565.
68. Bode A.P., Miller D.T. Analysis of platelet factor 3 in platelet concentrates stored for transfusion. Vox Sang 1986, 51:299-305.
69. Owens M.R., Holme S., Cardinali S. Platelet microvesicles adhere to subendothelium and promote adhesion of platelets. Thromb Res 1992, 66:247-258.
70. Hjort P.F., Perman V., Cronkite E.P. Fresh, disintegrated platelets in radiation thrombocytopenia: Correction of prothrombin consumption without correction of bleeding. Proc Soc Exp Biol Med 1959, 102:31-35.
71. McGill M., Fugman D.A., Vittorio N., et al. Platelet membrane vesicles reduced microvascular bleeding times in thrombocytopenic rabbits. J Lab Clin Med 1987, 109:127-133.
72. Chao F.C., Kim B.K., Houranieh A.M., et al. Infusible platelet membrane microvesicles: A potential transfusion substitute for platelets. Transfusion 1996, 36:536-542.
73. Graham S.S., Gonchoroff N.J., Miller J.L. Infusible platelet membranes retain partial functionality of the platelet GPIb/IX/V receptor complex. Am J Clin Pathol 2001, 115:144-147.
74. Galan A.M., Bozzo J., Hernandez M.R., et al. Infusible platelet membranes improve hemostasis in thrombocytopenic blood: Experimental studies under flow conditions. Transfusion 2000, 40:1074-1080.
75. Goodnough L.T., Kolodziej M., Ehlenbeck C. A phase I study of safety and efficacy for infusible platelet membrane in patients [Abstract]. Blood 1995, 86 ](Suppl. 1):610.
76. Scigliano E., Enright H., Telen M., et al. Infusible platelet membrane for control of bleeding in thrombocytopenic patients [Abstract]. Blood 1997, 90(Suppl. 1):267.
77. Arnold P., Djerassi I., Farber S., et al. The preparation and clinical administration of lyophilized platelet material to children with acute leukemia and aplastic anemia. J Pediatr 1956, 49:517-522.
78. Fliedner T.M., Sorensen D.K., Bond V.P., et al. Comparative effectiveness of fresh and lyophilized platelets in controlling irradiation hemorrhage in the rat. Proc Soc Exp Biol Med 1958, 99:731-733.
79. Jackson D.P., Sorensen D.K., Cronkite E.P., et al. Effectiveness of transfusions of fresh and lyophilized platelets in controlling bleeding due to thrombocytopenia. J Clin Invest 1959, 38:1689-1697.
80. Firkin B.G., Arimura G., Harrington W.J. A method for evaluating the hemostatic effect of various agents in thrombocytopenic rats and mice. Blood 1960, 15:388-394.
81. Read M.S., Reddick R.L., Bode A.P., et al. Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: Potential for long-term storage of dried platelets for transfusion. Proc Natl Acad Sci USA 1995, 92:397-401.
82. Bode A.P. Preclinical testing of lyophilized platelets as a product for transfusion medicine. Transfus Sci 1995, 16:183-185.
83. Valeri C.R., MacGregor H., Barnard M.R., et al. In vitro testing of fresh and lyophilized reconstituted human and baboon platelets. Transfusion 2004, 44:1505-1512.
84. Bode A.P., Read M.S., Reddick R.L. Activation and adherence of lyophilized human platelets on canine vessel strips in the baumgartner perfusion chamber. J Lab Clin Med 1999, 133:200-211.
85. Valeri C.R., MacGregor H., Barnard M.R., et al. Survival of baboon biotin-X-N-hydroxysuccinimide and (111) In-oxine-labelled autologous fresh and lyophilized reconstituted platelets. Vox Sang 2005, 88:122-129.
86. Fischer T.H., Merricks E.P., Bode A.P., et al. Thrombus formation with rehydrated, lyophilized platelets. Hematology 2002, 7:359-369.
87. Fischer T.H., Merricks E.P., Russell K.E., et al. Intracellular function in rehydrated lyophilized platelets. Br J Haematol 2000, 111:167-174.
88. Fischer T.H., Merricks E., Bellinger D.A., et al. Splenic clearance mechanisms of rehydrated, lyophilized platelets. Artif Cells Blood Substit Immobil Biotechnol 2001, 29:439-451.
89. Blajchman M.A., Lee D.H. The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes. Transfus Med Rev 1997, 11:95-105.
90. Crowe J.H., Carpenter J.F., Crowe L.M. The role of vitrification in anhydrobiosis. Annu Rev Physiol 1998, 60:73-103.
91. Crowe J.H., Crowe L.M., Oliver A.E., et al. The trehalose myth revisited: Introduction to a symposium on stabilization of cells in the dry state. Cryobiology 2001, 43:89-105.
92. Crowe J.H., Tablin F., Wolkers W.F., et al. Stabilization of membranes in human platelets freeze-dried with trehalose. Chem Phys Lipids 2003, 122:41-52.
93. Wolkers W.F., Walker N.J., Tablin F., et al. Human platelets loaded with trehalose survive freeze-drying. Cryobiology 2001, 42:79-87.
94. U.S.Food Drug Administration Department of Health and Human Services Agency response letter - GRAS notice No. GRN 000045 2000, October 5, Accessed September 18, 2005. Available at, U.S. Food and Drug Administration, Department of Health and Human Services, Rockville, MD. http://www.cfsan.fda.gov/~rdb/opa.
95. Choi E.S., Nichol J.L., Hokom M.M., et al. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995, 85:402-413.
96. Fujimoto T.T., Kohata S., Suzuki H., et al. Production of functional platelets by differentiated embryonic stem (ES) cells in vitro. Blood 2003, 102:4044-4051.
97. Agam G., Livne A.A. Erythrocytes with covalently bound fibrinogen as a cellular replacement for the treatment of thrombocytopenia. Eur J Clin Invest 1992, 22:105-112.
98. Levi M., Friederich P.W., Middleton S., et al. Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat Med 1999, 5:107-111.
99. Yen R.C.K., Ho T.W.C., Blajchman M.A. A new hemostatic agent: Thrombospheres shorten bleeding time in thrombocytopenic rabbits [Abstract]. Thromb Haemost 1995, 73:986.
100. Takeoka S., Teramura Y., Okamura Y., et al. Fibrinogen-conjugated albumin polymers and their interaction with platelets under flow conditions. Biomacromolecules 2001, 2:1192-1197.
101. Nishiya T., Kainoh M., Murata M., et al. Platelet interactions with liposomes carrying recombinant platelet membrane glycoproteins or fibrinogen: Approach to platelet substitutes. Artif Cells Blood Substit Immobil Biotechnol 2001, 29:453-464.
102. Nishiya T., Toma C. Interaction of platelets with liposomes containing dodecapeptide sequence from fibrinogen. Thromb Haemost 2004, 91:1158-1167.
103. Okamura Y., Takeoka S., Teramura Y., et al. Hemostatic effects of fibrinogen gamma-chain dodecapeptide-conjugated polymerized albumin particles in vitro and in vivo. Transfusion 2005, 45:1221-1228.
104. Coller B.S., Springer K.T., Beer J.H., et al. Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions. J Clin Invest 1992, 89:546-555.
105. Takeoka S., Teramura Y., Ohkawa H., et al. Conjugation of von Willebrand factor-binding domain of platelet glycoprotein Ib alpha to size-controlled albumin microspheres. Biomacromolecules 2000, 1:290-295.
106. Kitaguchi T., Murata M., Iijima K., et al. Characterization of liposomes carrying von Willebrand factorbinding domain of platelet glycoprotein Ibalpha: A potential substitute for platelet transfusion. Biochem Biophys Res Commun 1999, 261:784-789.
107. Nishiya T., Murata M., Handa M., et al. Targeting of liposomes carrying recombinant fragments of platelet membrane glycoprotein Ibalpha to immobilized von Willebrand factor under flow conditions. Biochem Biophys Res Commun 2000, 270:755-760.
108. Takeoka S., Teramura Y., Okamura Y., et al. Rolling properties of rGPIbalpha-conjugated phospholipid vesicles with different membrane flexibilities on vWf surface under flow conditions. Biochem Biophys Res Commun 2002, 296:765-770.
109. Rybak M.E., Renzulli L.A. A liposome based platelet substitute, the plateletsome, with hemostatic efficacy. Biomater Artif Cells Immobilization Biotechnol 1993, 21:101-118.
110. Coller B.S. Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: Defective platelet-fibrinogen interaction in thrombasthenia. Blood 1980, 55:169-178.
111. Agam G., Livne A. Passive participation of fixed platelets in aggregation facilitated by covalently bound fibrinogen. Blood 1983, 61:186-191.
112. Agam G., Livne A. Platelet-platelet recognition during aggregation: Distinct mechanisms determined by the release reaction. Thromb Haemost 1984, 51:145-149.
113. Beer J.H., Springer K.T., Coller B.S. Immobilized arg-gly-asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein IIb/IIIa receptor. Blood 1992, 79:117-128.
114. Alving B.M., Reid T.J., Fratantoni J.C., et al. Frozen platelets and platelet substitutes in transfusion medicine. Transfusion 1997, 37:866-876.
115. Perkins A.C., Frier M., Hindle A.J., et al. Human biodistribution of an ultrasound contrast agent (quantison) by radiolabelling and gamma scintigraphy. Br J Radiol 1997, 70:603-611.
116. Davies A.R., Judge H.M., May J.A., et al. Interactions of platelets with Synthocytes, a novel platelet substitute. Platelets 2002, 13:197-205.
117. Yen R.K.C., Ho T.W.C., Blajchman M.A. A novel approach to correcting the bleeding associated with thrombocytopenia [Abstract]. Transfusion 1995, 35:41S.
118. Sie P., Gillois M., Boneu B., et al. Reconstitution of liposomes bearing platelet receptors for human von Willebrand factor. Biochem Biophys Res Commun 1980, 97:133-138.
119. Baldassare J.J., Kahn R.A., Knipp M.A., et al. Reconstruction of platelet proteins into phospholipid vesicles. Functional proteoliposomes. J Clin Invest 1985, 75:35-39.
120. Parise L.V., Phillips D.R. Platelet membrane glycoprotein IIb-IIIa complex incorporated into phospholipid vesicles. Preparation and morphology. J Biol Chem 1985, 260:1750-1756.
121. Rybak M.E. Glycoproteins IIb and IIIa and platelet thrombospondin in a liposome model of platelet aggregation. Thromb Haemost 1986, 55:240-245.
122. Hayhoe F.G., Whitby L. The management of acute leukaemia in adults. Br J Haematol 1955, 1:1-19.
123. Schulman I., Currimbhoy Z., Smith C.H., et al. Phosphatides as platelet substitutes in blood coagulation. Ann N Y Acad Sci 1958, 75:195-202.
124. Galan A.M., Hernandez M.R., Bozzo J., et al. Preparations of synthetic phospholipids promote procoagulant activity on damaged vessels: Studies under flow conditions. Transfusion 1998, 38:1004-1010.
125. Galan A.M., Casals E., Estelrich J., et al. Possible hemostatic effect of synthetic liposomes in experimental studies under flow conditions. Haematologica 2002, 87:615-623.
126. Giles A.R., Mann K.G., Nesheim M.E. A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII. in vivo. Br J Haematol 1988, 69:491-497.
127. Ni H.Y., Giles A.R. Normalization of the haemostatic plugs of dogs with haemophilia A (factor VIII deficiency) following the infusion of a combination of factor Xa and phosphatidylcholine/phosphatidylserine vesicles. Thromb Haemost 1992, 67:264-271.
128. Tranholm M., Røjkjaer R., Pyke C., et al. Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits. Thromb Res 2003, 109:217-223.
129. Woods M.C., Gamble F.N., Furth J., et al. Control of the postirradiation hemorrhagic state by platelet transfusions. Blood 1953, 8:545-553.
130. Krishnamurti C., Maglasang P., Rothwell S.W. Reduction of blood loss by infusion of human platelets in a rabbit kidney injury model. Transfusion 1999, 39:967-974.
131. Vostal J.G., Reid T.J., Mondoro T.H. Summary of a workshop on in vivo efficacy of transfused platelet components and platelet substitutes. Transfusion 2000, 40:742-750.
132. Heddle N.M., Cook R.J., Webert K.E., et al. Biomedical Excellence for Safer Transfusion Working Party of the International Society for Blood Transfusion. Transfusion 2003, 43.